There are 130 to 150 million people with chronic Hepatitis C all over the world from which almost 500 000 die each year because of cirrhosis or cancer. This disease does not spread through food, water, or casual contact.
Hepatitis C is a liver infection caused by a virus which spreads through the blood or body fluids of an infected person.
You can be contaminated:
There are different genotypes of Hepatitis C in the world. In Algeria the most common one is genotype 1. It is also the case in the United States, Canada or France for example.
New treatments for Hepatits C were developed by multinational companies, but at a very high cost. Therefore BEKER® Laboratories decided to search for affordable solutions for patients with Hepatitis C.
Thus, and following the success BEKER® Laboratories experienced by the development of the generic version of Sofosbuvir, Sofos® as well as the Sofosbuvir/Ledipasvir combination, Sofosled® with 100% proven efficacy, they enriched the pipeline by the development and production of the generic version of Daclatasvir® to make treatment accessible to all patients no matter their genotype.
Dacla® 60mg is a drug taken with with Sofos® (Sofosbuvir 400mg) used to treat infection with hepatitis C in adults (18+), whatever the genotype. One daily pill is sufficient to eliminate the Hepatitis C virus from your blood after a while.
Dacla® is always taken with Sofos® (Sofosbuvir 400mg). Alone, it is not efficient. Please refer to your doctor for the details of your treatment.